CoreBone is developing a groundbreaking solution for articular cartilage regeneration, targeting a $2.5 billion market with few effective alternatives. Preclinical studies demonstrate outstanding ability to regenerate Hyaline based cartilage, addressing a critical gap in current treatment options. The existing gold standard, microfracture surgery, offers only 30% success rate while CoreBone aims for 70% success rate,
The innovation is powered by CoreBone’s proprietary coral cultivation technology, both regulatory-approved and environmentally sustainable.